Trial Profile
A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Gastrointestinal cancer; Lung cancer; Neuroendocrine tumours
- Focus Registrational; Therapeutic Use
- Acronyms RADIANT-4
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 15 Apr 2021 Results of post hoc pooled analysis from RADIANT-3 and RADIANT-4, published in the Cancer.
- 13 Sep 2020 This trial is completed in Austria (Global End Date: 07 Aug 2020), according to European Clinical Trials Database record.
- 01 Sep 2020 This trial has been completed in Poland.